ILMN
Illumina·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
High Gross Profit Margin
Significant Net Income Decline
High Cash/net Profit Ratio
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ILMN
Illumina, Inc.
A leading developer of life science tools and integrated systems for the analysis of genetic variation and function
Life Science Tools and Services
--
07/28/2000
NASDAQ Stock Exchange
8,970
12-31
Common stock
5200 Illumina Way, San Diego, California, 92122
Life science tool development, manufacturing
Illumina, Inc., is a leading developer, manufacturer and marketer of life science appliances and integrated systems for analyzing gene variation and gene function. The company was formed in California in April 1998 and reorganized in Delaware in July 2000. The company utilizes patented technology to provide a range of genetic analysis solutions as well as products and services for highly interconnected markets, including gene sequence, gene type, gene expression and molecular diagnostic markets. The company's customers include leading genomic research centers, academic institutions, government-administered laboratories, clinical research organizations, as well as pharmaceutical companies, biotechnology companies, agricultural product genome identification research and development companies and customer genome identification companies.
Earnings Call
Q1/2025
Estimate EPS0.94
Actual EPS0.97
Estimate Revenue1.03B
Actual Revenue1.04B
Illumina's Q1 2025: Navigating Contradictions in China Revenue, NovaSeq X Demand, and Tariff Impacts
May 19,2025 04:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS1.01
Actual EPS1.19
Estimate Revenue1.05B
Actual Revenue1.06B
Illumina's Q2 2025 Earnings Call: Unpacking Contradictions in Tariffs, NovaSeq X Transition, and Market Dynamics
Aug 01,2025 01:35
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS1.17
Actual EPS1.34
Estimate Revenue1.07B
Actual Revenue1.08B
Illumina's Q3 2025 Earnings Call: Contradictions in China Market and Regulatory Challenges, Instrument Expectations, and NovaSeq X Transition
Oct 30,2025 11:14
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ILMN has released its 2025 Q3 earnings. EPS was reported at 1.34, versus the expected 1.17, beating expectations. The chart below visualizes how ILMN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ILMN has released its 2025 Q3 earnings report, with revenue of 1.08B, reflecting a YoY change of 0.37%, and net profit of 150.00M, showing a YoY change of -78.72%. The Sankey diagram below clearly presents ILMN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
